<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344705</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART201701</org_study_id>
    <nct_id>NCT03344705</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM19 Cells</brief_title>
  <official_title>Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including
      B-cell Acute lymphoblastic Leukemia、B-cell Chronic Lymphocytic Leukemia、Non-Hodgkin's
      lymphoma) and Determine the Best Dosage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms,laboratory toxicities,and clinical events that are possibly,likely,or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>2. Overall response rate An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>IM19 CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM19 CAR-T</intervention_name>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>IM19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Two days before cell infusion,all patients will be treated with fludarabine for 3 days</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with CD19 positive relapsed or refractory B-cell malignancies, including
             B-cell Acute Lymphocytic Leukemia(ALL)、B-cell Chronic Lymphocytic
             Leukemia(CLL)、Non-Hodgkin's lymphoma(NHL).

        1)Patients with ALL:

          -  Previously treated with at least two courses of chemotherapy Ⅱ The interval of the
             last chemotherapy and disease progression is less than one year.

             Ⅲ Not suitable for allogeneic stem cell transplantation. 2)Patients with CLL:

          -  Previously treated with at least two courses of chemotherapy

             Ⅱ The interval of the last chemotherapy and disease progression is less than two
             years.

             Ⅲ Not suitable for allogeneic stem cell transplantation conditions or due to
             conditions to abandon allogeneic stem cell transplantation.

             3) Patients with DLBCL or FL、PMBCL:

          -  Patients who relapsed or were refractory after at least two previous treatments.

             Ⅱ Patients who relapsed after transplantation. 4)Patients who have relapsed or have
             refractory mantle cell lymphoma after at least one treatment.

             2.Measurable disease,including minimal residual disease. 3.Gender is not limited, to
             be aged 4 to 75 years 4.Expected survival &gt;3 months. 5.Eastern Cooperative Oncology
             Group(ECOG) score 0-2. 6.Women of childbearing potential must have a blood pregnancy
             test taken and proven negative prior to the treatment. All patients agree to use
             reliable methods of contraception during the trial period and until follow-up for the
             last time.

             7.Absence of symptoms of central nervous system(CNS) leukemia.

        Exclusion Criteria:

          1. Patients who have been treated with chemotherapy or radiotherapy within 2 weeks before
             blood collection.

          2. Patients have GVHD, which needs treatment with immunosuppressive agents,or patients
             with autoimmune diseases.

          3. Patient who have been treated with systemic steroid medication within two weeks of
             blood collection（Except for the recent or current use of inhaled steroids）.

          4. Patient who have been treated with stimulation of bone marrow hematopoietic cells
             generated drugs(Such as Recombinant Human Granulocyte Colony-stimulating Factor
             Injection) within 2 weeks before the blood collection period to use .

          5. The number of T cells in peripheral blood is lower than 2×10^8/L.

          6. Previously treatment with any gene therapy products.

          7. History of epilepsy or other CNS disease.

          8. New York Heart Association(NYHA) grade≥Ⅲ.

          9. Creatinine&gt; 1.5×normal value，Alanine transaminase(ALT) /Aspartate
             aminotransferase(AST)&gt;3×normal value，Bilirubin &gt;2×normal value.

         10. Degree of myeloproliferation： Ⅳ-V

         11. Active hepatitis B , hepatitis C or HIV infection and cytomegalovirus infection
             ,Epstein-Barr virus infection or any other uncontrolled active infection.

         12. Pregnancy or breast-feeding women.

         13. Any uncontrolled medical disorders that the researchers considered are not suitable to
             participate the clinical trial.

         14. Any situation that would increase dangerousness of subjects or disturb the outcome of
             the clinical study according to the researcher's evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmei Jing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin-an Lu, Dr</last_name>
    <phone>86-189-1157-6946</phone>
    <email>luxinan@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinan Lu, Dr</last_name>
      <phone>86-189-1157-6946</phone>
      <email>luxian@immunochina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

